Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan.

Jen-Shi Chen Li-Yuan BaiHsiao-Hsiang ChengStephen Lam ChanJi-Yan ZouXiaofeng ShiAude HouchardXuan-Mai Truong-ThanhMing-Huang Chen

Published in: Oncology and therapy (2024)

Lanreotide autogel was well tolerated and showed good tumor control rate in a real-world setting. These findings align with results from previous studies in Caucasian, Japanese, and Korean patients, thus supporting lanreotide autogel for treating patients with GEP-NETs of Chinese ethnicity.

Keyphrases

neuroendocrine tumors
end stage renal disease
ejection fraction
newly diagnosed
healthcare
prognostic factors
peritoneal dialysis
clinical practice
patient reported